Eledon Pharmaceuticals, Inc.Eledon Pharmaceuticals, Inc.Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪97.81 M‬USD
−1.49USD
‪−40.33 M‬USD
‪38.48 M‬
Beta (1Y)
−0.38

About Eledon Pharmaceuticals, Inc.

CEO
David-Alexandre C. Gros
Headquarters
Irvine
Website
Employees (FY)
20
Founded
2004
FIGI
BBG00241S542
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ELDN is 2.54 USD — it has increased by 2.83% in the past 24 hours. Watch Eledon Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Eledon Pharmaceuticals, Inc. stocks are traded under the ticker ELDN.
ELDN stock has risen by 2.83% compared to the previous week, the month change is a 14.77% fall, over the last year Eledon Pharmaceuticals, Inc. has showed a 90.98% increase.
We've gathered analysts' opinions on Eledon Pharmaceuticals, Inc. future price: according to them, ELDN price has a max estimate of 28.00 USD and a min estimate of 7.00 USD. Watch ELDN chart and read a more detailed Eledon Pharmaceuticals, Inc. stock forecast: see what analysts think of Eledon Pharmaceuticals, Inc. and suggest that you do with its stocks.
ELDN reached its all-time high on Sep 17, 2014 with the price of 4,864.87 USD, and its all-time low was 1.07 USD and was reached on Nov 9, 2023. View more price dynamics on ELDN chart.
See other stocks reaching their highest and lowest prices.
ELDN stock is 5.76% volatile and has beta coefficient of −0.38. Track Eledon Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Eledon Pharmaceuticals, Inc. there?
Today Eledon Pharmaceuticals, Inc. has the market capitalization of ‪97.81 M‬, it has decreased by 2.41% over the last week.
Yes, you can track Eledon Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Eledon Pharmaceuticals, Inc. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ELDN earnings for the last quarter are −0.34 USD per share, whereas the estimation was −0.37 USD resulting in a 7.01% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about Eledon Pharmaceuticals, Inc. earnings.
Eledon Pharmaceuticals, Inc. revenue for the last quarter amounts to 0 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ELDN net income for the last quarter is ‪−10.30 M‬ USD, while the quarter before that showed ‪−9.63 M‬ USD of net income which accounts for −6.95% change. Track more Eledon Pharmaceuticals, Inc. financial stats to get the full picture.
No, ELDN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 15, 2024, the company has 20.00 employees. See our rating of the largest employees — is Eledon Pharmaceuticals, Inc. on this list?
Like other stocks, ELDN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eledon Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eledon Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eledon Pharmaceuticals, Inc. stock shows the neutral signal. See more of Eledon Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.